Medical Device Patent Landscape. Evidence Before the Decision.

A medical device patent landscape is the structured read of who is filing, where, and on what across the medtech industry — the map an IP, strategy or R&D team uses to see filing momentum, the assignees that dominate a subfield, and the white space still open to a new entrant. The field is unusually rich to map: on the EPO’s primary record, medical technology drew 15,701 European patent applications in 2024, and for US-based innovators it remained the single most-filed field of technology. This page shows what the current data reveals and how a rigorous analysis turns it into decisions.

What the Medical Device Patent Landscape Shows in 2024

A landscape turns a scattered mass of filings into three answers a medtech team can act on: is innovation in a subfield accelerating or cooling, which companies already hold the ground, and where is the ground still open. Each is a different cut of the same public record — the filing trend, the assignee ranking, and the white-space gap — and each drives a different decision, from where to file next to who to license from or design around.

The macro backdrop makes the exercise worth doing well. MedTech Europe, drawing on EPO data, puts the European medical-technology market at roughly €170 billion in 2024, spread across some 38,000 companies of which about 90% are SMEs, employing more than 930,000 people. It is a fragmented, fast-innovating field where patent position, not scale alone, decides who captures a new procedure or platform. Medical technology accounted for about 7.9% of all EPO filings in 2024, and over the last two decades EPO medtech filings have almost tripled.

Because the field is so fragmented, the map matters more than in a concentrated industry. A single strong claim held by a university spin-out can block a multinational’s launch, and a cluster that looks crowded at the headline level often hides an open lane one layer down. Reading that requires the primary record, not a market-report summary.

Filing Trends: Where Medtech Sits Among the Fields

Filing trend is the first layer, and 2024 marks a genuine inflection. On the EPO Patent Index, medical technology recorded 15,701 applications and slipped to the fourth-largest field, down about 3.0% year on year, after holding the number-one rank in 2020 and 2021. It was overtaken by computer technology (16,815, +3.3%, driven by AI), electrical machinery, apparatus and energy (16,142, +8.9%), and digital communication (15,983). The headline is not decline so much as the rest of the system racing ahead on AI and electrification.

The origin cut tells a sharper story. Among US-based applicants, medical technology is still the number-one field at the EPO, with 5,995 applications in 2024 — ahead of computer technology and digital communication. Filing origins for the field split roughly 40.5% EPO states, 38.2% United States and 21.3% rest of world, so a credible read has to combine the US and European records rather than either alone.

The US domestic record adds a third view. At the USPTO, medical devices are examined mainly in Technology Center 3700, and the office issued 326,921 utility patents across all fields in fiscal 2024 — a reminder that European application counts capture only part of a global portfolio. Crossing EPO, USPTO and WIPO data is what stops a landscape from mistaking one office’s slowdown for a real cooling in the technology.

Globally, WIPO’s World Intellectual Property Indicators put medical technology at about 4.9% of all published patent applications in 2023 (rank five), having grown roughly 7.1% across the 2012–2022 decade. WIPO also flags the Netherlands and Switzerland as the economies that specialise most heavily in the field — a concentration any competitive read should expect to see, and a reason to weight European filings when scouting for licensable assets.

Who Owns the Field: Leading Medtech Assignees

The assignee ranking is where a landscape stops being a chart and starts naming competitors. On the EPO’s medical-technology field, Royal Philips led all applicants in 2024 with 594 filings, followed by Johnson & Johnson and Medtronic — a top tier of diversified device houses rather than a single dominant filer.

Depth of portfolio matters as much as annual flow. Philips reports a global portfolio of about 50,500 patent rights and roughly €1.7 billion of R&D in 2024, close to half of it in informatics and AI. Siemens Healthineers reports about 16,000 granted patents and €1,918 million of R&D in fiscal 2024. On the US side, Medtronic spent about $2.735 billion on R&D in fiscal 2024, Abbott about $2.844 billion, and Boston Scientific about $1,615 million, up roughly 14% on the prior year. Reading spend alongside filing count separates the houses defending a franchise from those actively expanding into new ground.

Concentration also varies sharply by subfield, which is why a single leaderboard misleads. The right cut groups assignees by the position they actually hold:

• Diversified device majors — Philips, Johnson & Johnson, Medtronic, Siemens Healthineers: broad portfolios spanning imaging, surgical, cardiovascular and monitoring.
• Category specialists — Boston Scientific, Abbott, Dexcom, Intuitive Surgical: deep, defensible clusters around one franchise such as electrophysiology, glucose monitoring or surgical robotics.
• SMEs and university spin-outs — the roughly 90% of the field that files thinly but often owns the earliest, broadest claims in an emerging subfield, and the most likely licensing or acquisition targets.

The Technology Clusters Driving Growth

Splitting the field into technology clusters is what makes a landscape strategically useful, because each cluster sits at a different point on its innovation curve. Four are drawing disproportionate attention in the current record.

• Surgical robotics — a maturing but still-expanding cluster where a few incumbents hold the core multi-arm platform claims, pushing new entrants toward end-effectors, articulation and haptics.
• AI-enabled diagnostics and digital health — the fastest-moving cluster: the FDA’s list of AI/ML-enabled medical devices reached 1,016 authorisations by December 2024, with radiology dominant, and EPO AI filings feed directly into it.
• Wearables and continuous monitoring — continuous glucose monitoring is the standout, with Dexcom (revenue about $4.03 billion in 2024) and Abbott anchoring the cluster, and the first over-the-counter CGM cleared by the FDA in 2024 opening a new consumer lane.
• Neuromodulation and minimally invasive devices — concentrated clusters where Medtronic, Abbott and Boston Scientific hold most of the position, and design-around opportunities cluster at the edges.

The value of the cluster view is that it prices each move differently. Entering a late-stage cluster as a me-too builder is a losing game; entering at an early-stage interface, or licensing a specialist’s asset to leapfrog a maturing platform, is where the return sits. A cluster map is what tells the two apart.

White Space: Where the Field Is Still Open

White space is the payoff question: where is filing density still low enough to claim position? The analysis finds it by crossing the trend and assignee layers — looking for subfields with rising problem-relevance but thin, fragmented ownership, or with ageing core patents nearing expiry.

In the current medtech record, the openings tend to sit one layer below the headline clusters: at the interfaces (sensor-to-AI pipelines, device-to-cloud data rights), in the design-around space left by expiring platform patents, and in geographies where a technology is filed heavily in the US and Europe but sparsely elsewhere. White space is never the absence of filings — it is a defensible gap between where the problem is heading and where the claims currently sit.

Testing a candidate gap is a discipline of its own. A genuine opening survives three checks: the problem it addresses is growing, the surrounding claims leave room to draft around, and no dominant assignee is already filing quietly into it. A gap that fails any one of those is a trap, not an opportunity, and finding that out on the patent record is far cheaper than finding it out in litigation.

Regulation, Freedom to Operate and Deals

Regulation is a landscape force in medtech in a way it is not in most fields, because an approval pathway can make or strand a patent’s commercial value. Two forces dominate the current map. The FDA’s AI/ML device authorisations — 1,016 by the end of 2024 — signal where diagnostic IP can actually reach market, and a granted predicate lineage is often worth more than a broad claim with no clearance path.

In Europe, the Medical Device Regulation transition under Regulation (EU) 2023/607 extended key deadlines to 31 December 2027 for higher-risk class III and class IIb implantable devices and 31 December 2028 for many class IIa, IIb and class I sterile or measuring devices — conditional on a conformity-assessment application having been filed by 26 May 2024. The effect is that portfolio and product-launch timing now have to be read against certificate expiry, not just patent term.

Read properly, the analysis feeds three decisions at once: where to file next, how to design around a blocking cluster for freedom to operate, and which portfolios are worth acquiring or licensing. Each draws on a different layer of the same map, which is why a landscape built for one question can usually answer the other two.

How to Commission a Landscape Study

Commissioning the study is less about volume of data than about the questions it is built to answer. A landscape worth acting on starts from a decision — enter a subfield, clear freedom to operate, price an acquisition — and works back to the specific filings, assignees and expiries that decide it.

At PerspireIP we build each medical device patent landscape on the primary record — EPO, USPTO and WIPO data, read together and cited — then layer assignee benchmarking, a technology-cluster map and a white-space readout on top. The deliverable is not a dashboard but a written point of view a board, an R&D lead or a deal team can act on, with every number traceable to its source.

That primary-source discipline is the whole point. Anyone can buy a chart; what changes a decision is knowing which claims block a launch, which assignee is quietly building in an adjacent lane, and which core patent expires in time to matter. That is the difference between a report that sits in a drawer and one a team files, licenses or designs around.

What You Receive

• A filing-trend analysis — medtech application and grant momentum by year, office and technology subfield, read across the EPO, USPTO and WIPO records
• Top-assignee benchmarking — who owns the field (Philips, J&J, Medtronic, Siemens Healthineers and the specialists), how fast each is growing, and where portfolios overlap
• A technology-cluster map splitting medtech into surgical robotics, AI diagnostics, continuous monitoring, neuromodulation and minimally invasive devices
• A white-space readout — the subfields, interfaces and geographies where filing density is still low enough to claim position
• A regulatory overlay — FDA AI/ML authorisations and EU MDR timing mapped against patent term and freedom to operate
• A primary-source evidence pack citing EPO, WIPO and company data behind every number

Data Sources & References

This analysis draws on primary patent and market data:

• EPO Patent Index 2024 — Medical technology at 15,701 European applications in 2024 (rank four, about -3.0%), still the number-one field for US-based applicants (5,995), with Royal Philips leading medtech filers.
• WIPO World Intellectual Property Indicators 2025 — Patents highlights — Medical technology at about 4.9% of global published applications (2023), and the Netherlands and Switzerland as the economies specialising most in the field.
• MedTech Europe — The European Medical Technology Industry in Figures 2025 — European medtech market of roughly €170 billion in 2024, medical technology at about 7.9% of EPO filings, and filing origins split across EPO states, the US and the rest of the world.
• FDA — Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices — The FDA list of AI/ML-enabled medical devices, which reached 1,016 authorisations by December 2024, radiology dominant.

Request a Medical Device Patent Landscape

Get a primary-source medtech landscape built around your decision — entry, freedom to operate or acquisition.

Related PerspireIP work: Technology Scouting · Patent White-Space Analysis · Competitive Patent Landscape Analysis.

Frequently Asked Questions